

**Data Sheet**

<b>NAME:</b>	HIV-1 Drug (Carbocyclic Nucleoside) Resistant Variant – K65R/M184V.
<b>REPOSITORY REFERENCE:</b>	ARP1006
<b>DERIVATION:</b>	Derived from HXB2 by in vitro selection with 1592U89. RT mutation K→R at position 65 and M→V at position 184.
<b>ORIGINATORS DESIGNATION:</b>	HXB RT Mutant 65/184.
<b>CHARACTERISTICS:</b>	Confers resistance (seven- to eightfold) to carbocyclic nucleoside (1592U89), increased cross- resistance to ddI, ddC & 3TC.
<b>CELLS FOR PROPAGATING:</b>	MT4
<b>PRESENTATION:</b>	Supplied as cell-free culture supernatants from MT4 cells.
<b>CULTURE MEDIUM:</b>	RPMI 1640, Foetal calf serum 10%
<b>STORAGE:</b>	-70°C or below.
<b>SOURCE:</b>	Drs M Tisdale and D Cousens, Glaxo Welcome R & D, Herts.
<b>REFERENCE:</b>	Tisdale M et al, Antimicrobial Agents and Chemotherapy, May1997 Vol 41, No.5 p1094-1098.

**ACKNOWLEDGEMENTS:**

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the “Acknowledgements” section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)